1. Home
  2. GNL vs AGIO Comparison

GNL vs AGIO Comparison

Compare GNL & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Net Lease Inc.

GNL

Global Net Lease Inc.

N/A

Current Price

$9.36

Market Cap

1.9B

Sector

Real Estate

ML Signal

N/A

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

N/A

Current Price

$27.95

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GNL
AGIO
Founded
2011
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
GNL
AGIO
Price
$9.36
$27.95
Analyst Decision
Buy
Buy
Analyst Count
2
8
Target Price
$9.50
$37.63
AVG Volume (30 Days)
1.8M
742.0K
Earning Date
01-01-0001
05-15-2026
Dividend Yield
8.10%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,011,000.00
Revenue This Year
N/A
$75.68
Revenue Next Year
N/A
$167.63
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.51
$22.24
52 Week High
$10.04
$46.00

Technical Indicators

Market Signals
Indicator
GNL
AGIO
Relative Strength Index (RSI) 45.95 47.00
Support Level $9.28 $26.40
Resistance Level $9.66 $29.49
Average True Range (ATR) 0.21 1.16
MACD -0.06 -0.16
Stochastic Oscillator 28.47 29.40

Price Performance

Historical Comparison
GNL
AGIO

About GNL Global Net Lease Inc.

Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: